nach oben

American Journal of Cardiovascular Drugs

Erschienen in:

22.01.2024 | Systematic Review

SAMe-TT₂R₂ Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis

verfasst von: Natnicha Poonchuay, Surasak Saokaew, Supatcha Incomenoy

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Sex, age, medical history, treatment, tobacco use, and race (SAMe-TT₂R₂) score helps detect patients at risk of suboptimal anticoagulation control. A score above two suggests poor control; however, non-Caucasian status being assigned two points might hinder the recognition of poor control in patients of other races.

Objective

To evaluate the SAMe-TT₂R₂ score’s ability to predict poor anticoagulation control [defined as time in therapeutic range (TTR) < 60–70%] in Asian and non-Asian populations on vitamin K antagonists (VKAs).

Methods

We searched PubMed, Cochrane Library, Scopus, SpringerLink, and Web of Science using the keyword “SAMe-TT₂R₂.” Articles published before April 2022 were screened. We gathered mean TTR and diagnostic accuracy data for different SAMe-TT₂R₂ thresholds and conducted meta-analyses using random-effects models.

Results

A total of 30 studies were included (N = 36,690). The overall mean TTR differences were − 4.88 and − 6.41 for the cutoffs of ≥ 3 and ≥ 4, respectively. For non-Asian patients, the mean TTR differences were − 3.86, − 5.12, and − 8.09 for the cutoffs ≥ 2, ≥ 3, and ≥ 4, respectively. For Asian patients, the mean TTR differences were − 3.99 and − 4.07 for the cut-offs ≥ 3 and ≥ 4, respectively. The highest positive likelihood ratio (LR+) for the Asian subgroup was 1.17 [95% confidence interval (CI): 1.06–1.28; I² = 0%, p heterogeneity = 0.500] at cutoff ≥ 4 and for the non-Asian subgroup, at cut-off ≥ 3, the LR+ was 1.24 (95% CI 1.14–1.34; I² = 0% p heterogeneity = 0.455). The lowest LR− was found at a lower cutoff for both races (at cutoff ≥ 3 and ≥ 2 for Asian and non-Asian subgroups, respectively). The pooled results of other accuracy parameters were modest at all cutoffs, except for the sensitivity at cutoff ≥ 3 in the Asian subgroup (83.05%).

Conclusion

Our study results suggest that a higher SAMe-TT₂R₂ score resulted in a greater reduction of TTR among Asian and all races. The accuracy parameters showed the highest sensitivity for poor TTR at the SAMe-TT₂R₂ cutoff of ≥ 3 for Asian patients. However, the ability to identify patients likely to have poor TTR was limited. Further research is needed to enhance the risk assessment for poor anticoagulation control with VKAs.

Registration

The protocol of this systematic review was registered in the International Prospective Register of Scientific Reviews: PROSPERO, registration number CRD42021291865.

Graphical Abstract

Nur mit Berechtigung zugänglich

Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–21. https://doi.org/10.1177/1747493019897870.CrossRefPubMed

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.CrossRefPubMed

Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–608. https://doi.org/10.1016/j.chest.2021.07.055.CrossRefPubMed

Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e152S – e184.CrossRefPubMedPubMedCentral

Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. J Ame College Cardiol. 2003;41(9):1633–52.CrossRef

Rosendaal F, Cannegieter S, Van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(03):236–9.CrossRefPubMed

Haas S, Ten Cate H, Accetta G, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS ONE. 2016;11(10): e0164076.CrossRefPubMedPubMedCentral

Senoo K, Lau YC, Lip GY. Updated NICE guideline: management of atrial fibrillation (2014). Milton Park: Taylor & Francis; 2014. p. 1037–40.

Ogawa S, Aonuma K, Tse H-F, et al. The APHRS’s 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm. 2013;29(3):190–200. https://doi.org/10.1016/j.joa.2013.03.002.CrossRef

10.

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Kardiol Pol. 2016;74(12):1359–469.CrossRefPubMed

11.

Chiang C-E, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33(4):345–67. https://doi.org/10.1016/j.joa.2017.05.004.CrossRefPubMedPubMedCentral

12.

Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013;144(5):1555–63. https://doi.org/10.1378/chest.13-0054.CrossRefPubMed

13.

Limdi NA, Brown TM, Yan Q, et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126(4):539–45.CrossRefPubMedPubMedCentral

14.

Shen AY-J, Yao JF, Brar SS, et al. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39(10):2736–43.CrossRefPubMed

15.

Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med. 2005;352(22):2285–93.CrossRefPubMed

16.

Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111(5):789–97. https://doi.org/10.1160/th13-11-0948.CrossRefPubMed

17.

Romiti GF, Corica B, Proietti M, et al. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. EClinicalMedicine. 2023;63: 102039. https://doi.org/10.1016/j.eclinm.2023.102039.CrossRefPubMedPubMedCentral

18.

van Miert JH, Bos S, Veeger NJ, Meijer K. Clinical usefulness of the SAMe-TT2R2 score: a systematic review and simulation meta-analysis. PLoS ONE. 2018;13(3): e0194208. https://doi.org/10.1371/journal.pone.0194208.CrossRefPubMedPubMedCentral

19.

Krittayaphong R, Winijkul A, Pirapatdit A, et al. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J. 2020;61(12):641–6. https://doi.org/10.11622/smedj.2019143.CrossRefPubMedPubMedCentral

20.

Fauchier L, Angoulvant D, Lip GY. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace. 2015;17(5):671–3. https://doi.org/10.1093/europace/euv088.CrossRefPubMed

21.

Roldán V, Cancio S, Gálvez J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective “real-world” inception cohort study. Am J Med. 2015;128(11):1237–43. https://doi.org/10.1016/j.amjmed.2015.05.036.CrossRefPubMed

22.

Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.CrossRefPubMed

23.

Shor E, Roelfs D, Vang ZM. The “Hispanic mortality paradox” revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants’ mortality. Soc Sci Med. 2017;186:20–33. https://doi.org/10.1016/j.socscimed.2017.05.049.CrossRefPubMed

24.

Schünemann HJ, Vist GE, Higgins JP et al. Interpreting results and drawing conclusions. Cochrane handbook for systematic reviews of interventions. 2019:403–31.

25.

Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106–10. https://doi.org/10.1136/bmj.39500.677199.AE.CrossRefPubMedPubMedCentral

26.

Park YK, Lee MJ, Kim JH, et al. Lack of association of clinical factors (SAMe-TT2R2) with CYP2C9/VKORC1 genotype and anticoagulation control quality. J Stroke. 2015;17(2):192–8. https://doi.org/10.5853/jos.2015.17.2.192.CrossRefPubMedPubMedCentral

27.

Chan PH, Hai JJ, Chan EW, et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS ONE. 2016;11(3): e0150674. https://doi.org/10.1371/journal.pone.0150674.CrossRefPubMedPubMedCentral

28.

Bernaitis N, Ching CK, Chen LP, et al. The sex, age, medical history, treatment, tobacco use, race risk (SAMe TT2R2) score predicts warfarin control in a Singaporean population. J Stroke Cerebrovasc Dis. 2017;26(1):64–9. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.08.030.CrossRefPubMed

29.

Leedumrongwattanakul A. SAMe-TT2R2 score for prediction of anticoagulation control in Thai patients with non-valvular atrial fibrillation. J Med Assoc Thailand. 2021. https://doi.org/10.35755/jmedassocthai.2021.06.12415.CrossRef

30.

Lertsanguansinchai P, Huntrakul A, Rungpradubvong V, Chokesuwattanaskul R, Prechawat S. Factors predicting poor anticoagulant control on warfarin in a Thai population with non-valvular atrial fibrillation (NVAF): the ACAChE score. Int J Arrhythm. 2021;22(1):1–11.CrossRef

31.

Li Y, Yu J, Kuang Y, et al. Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study. Curr Med Res Opin. 2020;36(9):1433–9. https://doi.org/10.1080/03007995.2020.1796611.CrossRefPubMed

32.

Methavigul K. Proportion of Thai patients with atrial fibrillation receiving warfarin with labile inr in each group of SAMeTT2R2 score. J Med Assoc Thailand. 2018;101(2):189–93.

33.

Methavigul K. Use of SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with atrial fibrillation receiving warfarin in Thailand. J Med Assoc Thailand. 2020;103(6):548–52. https://doi.org/10.35755/jmedassocthai.2020.06.10827.CrossRef

34.

Liu J, Wang N, Qin L, et al. Integrating genotypes in the SAMe-TT2R2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. Int J Cardiol. 2017;241:358–63. https://doi.org/10.1016/j.ijcard.2017.04.092.CrossRefPubMed

35.

Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace. 2015;17(5):711–7. https://doi.org/10.1093/europace/euu353.CrossRefPubMed

36.

Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127(11):1083–8. https://doi.org/10.1016/j.amjmed.2014.05.023.CrossRefPubMed

37.

Poli D, Antonucci E, Testa S, Lip GY. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med. 2014;9(4):443–7. https://doi.org/10.1007/s11739-014-1065-8.CrossRefPubMed

38.

Ruiz-Ortiz M, Bertomeu V, Cequier Á, Marín F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost. 2015;114(4):695–701. https://doi.org/10.1160/th15-02-0169.CrossRefPubMed

39.

Lobos-Bejarano JM, Castellanos Rodríguez A, Barrios V, et al. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. Int J Clin Pract. 2017. https://doi.org/10.1111/ijcp.12974.CrossRefPubMed

40.

Palareti G, Antonucci E, Lip GY, et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost. 2016;115(6):1101–8. https://doi.org/10.1160/th15-10-0830.CrossRefPubMed

41.

Proietti M, Lane DA, Lip GY. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: observations from the SPORTIF trials. Int J Cardiol. 2016;216:168–72. https://doi.org/10.1016/j.ijcard.2016.04.131.CrossRefPubMed

42.

Bryk AH, Plens K, Undas A. Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation. Cardiol J. 2017;24(5):477–83. https://doi.org/10.5603/CJ.a2017.0038.CrossRefPubMed

43.

Demelo-Rodríguez P, Postigo-Esteban A, García-Fernández-Bravo I, et al. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists. Thromb Res. 2016;147:58–60. https://doi.org/10.1016/j.thromres.2016.09.021.CrossRefPubMed

44.

Kataruka A, Kong X, Haymart B, et al. SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: the MAQI2 experience. Vasc Med. 2017;22(3):197–203. https://doi.org/10.1177/1358863X16682863.CrossRefPubMedPubMedCentral

45.

Pivatto F, Scheffel RS, Ries L, et al. SAMe-TT 2 R 2 score in the outpatient anticoagulation clinic to predict time in therapeutic range and adverse events. Arq Bras Cardiol. 2017;108:290–6. https://doi.org/10.5935/abc.20170052.CrossRef

46.

Szymanski FM, Lip GY, Filipiak KJ, Platek AE, Karpinski G. Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea. Int J Cardiol. 2016;204:200–5. https://doi.org/10.1016/j.ijcard.2015.11.158.CrossRefPubMed

47.

Barco S, Granziera S, Coppens M, et al. Determinants of the quality of warfarin control after venous thromboembolism and validation of the SAMe-TT2-R2 score: an analysis of Hokusai-VTE. Thromb Haemost. 2019;119(04):675–84. https://doi.org/10.1055/s-0039-1678546.CrossRefPubMed

48.

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, et al. Quality of oral anticoagulation with vitamin K antagonists in “real-world” patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2018;20(9):1435–41. https://doi.org/10.1093/europace/eux314.CrossRefPubMed

49.

Mora-Llabata V, Dubois-Marqués D, Moreno-Prat M, et al. Utilidad marginal de la escala SAMe-TT2R2 en la predicción de la calidad de la anticoagulación oral con acenocumarol en el “mundo real.” Rev Colomb Cardiol. 2018;25(3):185–91. https://doi.org/10.1016/j.rccar.2017.10.004.CrossRef

50.

Bernaitis N, Badrick T, Anoopkumar-Dukie S. The SAMe–TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia. J Thromb Thrombol. 2020;50(3):614–8. https://doi.org/10.1007/s11239-020-02068-w.CrossRef

51.

Bernaitis N, Clark G, Kohja S, Leong S, Anoopkumar-Dukie S. The SAMe-TT(2)R(2) score predicts warfarin control in an australian population with atrial fibrillation. J Clin Med. 2019. https://doi.org/10.3390/jcm8060882.CrossRefPubMedPubMedCentral

52.

Del-Toro-Cervera J, Demelo-Rodriguez P, Galeano-Valle F, et al. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. Thromb Res. 2020;194:178–82. https://doi.org/10.1016/j.thromres.2020.06.022.CrossRefPubMed

53.

Wang K, Lu Y, Simegn MA, Xue H, Asinger RW. Use of SAMe-TT2R2 in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation. J Thromb Thrombolysis. 2022;55:1–6.CrossRefPubMed

54.

Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016;48(5):1369–76. https://doi.org/10.1183/13993003.00280-2016.CrossRefPubMed

55.

Incomenoy S, Saokaew S, Poonchuay N. SAMe-TT2R2 to predict clinical outcomes and time in therapeutic range in patients on vitamin K antagonists: a systematic review and meta-analysis. Ann Pharmacother. 2023. https://doi.org/10.1177/10600280231166643.CrossRefPubMed

56.

Golwala H, Jackson LR 2nd, Simon DN, et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016;174:29–36. https://doi.org/10.1016/j.ahj.2015.10.028.CrossRefPubMed

57.

Zawawi NA, Abdul Halim Zaki I, Ming LC, Goh HP, Zulkifly HH. Anticoagulation control in different ethnic groups receiving vitamin K antagonist for stroke prevention in atrial fibrillation. Front Cardiovasc Med. 2021;8:736143. https://doi.org/10.3389/fcvm.2021.736143.CrossRefPubMedPubMedCentral

58.

Ambe K, Akita A, Wei J, et al. Comparison of efficacy and safety of direct oral anticoagulants and warfarin between patients in Asian and non-Asian regions: a systematic review and meta-regression analysis. Clin Pharmacol Ther. 2023. https://doi.org/10.1002/cpt.2881.CrossRefPubMed

59.

Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83. https://doi.org/10.1016/s0140-6736(10)61194-4.CrossRefPubMed

60.

Al-Eitan LN, Almasri AY, Khasawneh RH. Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi Pharm J. 2019;27(4):484–90. https://doi.org/10.1016/j.jsps.2019.01.011.CrossRefPubMedPubMedCentral

61.

Williams BA, Evans MA, Honushefsky AM, Berger PB. Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation. J Am Heart Assoc. 2017;6(10): e006669. https://doi.org/10.1161/JAHA.117.006669.CrossRefPubMedPubMedCentral

62.

Lin KJ, Singer DE, Glynn RJ, et al. Prediction score for anticoagulation control quality among older adults. J Am Heart Assoc. 2017. https://doi.org/10.1161/jaha.117.006814.CrossRefPubMedPubMedCentral

63.

Methavigul K, Yindeengam A, Krittayaphong R. Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT2R2 score. BMC Cardiovasc Disord. 2023;23(1):43. https://doi.org/10.1186/s12872-023-03053-w.CrossRefPubMedPubMedCentral

Titel: SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis
verfasst von: Natnicha Poonchuay
Surasak Saokaew
Supatcha Incomenoy
Publikationsdatum: 22.01.2024
Verlag: Springer International Publishing
Erschienen in: American Journal of Cardiovascular Drugs / Ausgabe 2/2024
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-023-00623-3

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

SAMe-TT₂R₂ Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis

Abstract

Background

Objective

Methods

Results

Conclusion

Registration

Graphical Abstract

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Registration

Graphical Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Management of Hypertension in the Asia-Pacific Region: A Structured Review

Efficacy of Intravenous Iron in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Systematic Review and Meta-Analysis of Randomized Control Trials

The Rationale for Using Fixed-Dose Combination Therapy in the Management of Hypertension in Colombia: A Narrative Review

Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis

Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”

New Perspectives on the Role and Therapeutic Potential of Melatonin in Cardiovascular Diseases

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie